It is with heavy hearts that we announce the passing of Dr. Rahul Reddy. Click here to read more
It is with heavy hearts that we announce the passing of Dr. Rahul Reddy. Click here to read more Patient Portal Career Center (602) 242-4928

Sustained-Release Drug Implants for Retinal Disease: A Game Changer?

Managing retinal diseases often requires frequent treatments, such as eye injections to control conditions like wet age-related macular degeneration (AMD) or diabetic retinopathy. While these injections are effective, the frequency — sometimes monthly — can be burdensome for patients and caregivers. Enter sustained-release drug implants, a new approach designed to reduce treatment burden while maintaining vision protection.

Sustained-release implants, also called port delivery systems, are tiny devices surgically implanted in the eye. They slowly release medication, such as anti-VEGF therapy, over weeks or months. Instead of monthly injections, patients may only need a refill procedure periodically, which can significantly reduce clinic visits and improve quality of life.

The implant sits just inside the eye and continuously delivers the drug at a controlled rate. When the medication is depleted, the device can be refilled in the office without removing the implant. This method keeps the eye consistently treated, avoiding the peaks and troughs that can occur with traditional injections, which may help maintain more stable vision over time:

  • Fewer injections: For many patients, sustained-release implants dramatically reduce the number of office visits and needle procedures.
  • Stable medication levels: Continuous delivery can provide more consistent therapeutic effects, potentially improving outcomes.
  • Improved convenience: Reduced treatment frequency is especially helpful for patients with mobility challenges, busy schedules or difficulty traveling to the clinic.
  • Lower stress and anxiety: Many patients experience injection-related anxiety. Fewer injections can ease this emotional burden.

While sustained-release implants are promising, they are not appropriate for everyone. Implant surgery carries its own risks, including infection, implant displacement or eye pressure changes. Long-term studies are ongoing to determine the durability, safety and effectiveness compared with traditional injection schedules. Your ophthalmologist will evaluate whether this technology is suitable based on your retinal condition, health status and treatment goals.

Sustained-release drug delivery represents a major step toward personalized, patient-friendly retinal therapy. By minimizing injection frequency and maintaining consistent drug levels, these implants could transform the management of chronic retinal diseases. Research continues to refine implant designs, explore new medications and expand indications, bringing hope for even better vision preservation in the years ahead.

If you or a loved one requires frequent retinal injections, ask your ophthalmologist whether a sustained-release implant could be right for you. Understanding your options today can help protect your vision while reducing treatment burden and improving overall quality of life.

Contact Associated Retina Consultants at 602-242-4928 or WEBSITE.